---
figid: PMC3551337__cjcr-24-04-374-f2
figtitle: Major pathogenic lesions in MCL
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3551337
filename: cjcr-24-04-374-f2.jpg
figlink: /pmc/articles/PMC3551337/figure/f2/
number: F2
caption: Major pathogenic lesions in MCL. The B-cell receptor (BCR) signaling pathway
  is initiated through the phosphorylation of coreceptors Igα (CD79α) and Igβ (CD79β),
  which recruits spleen tyrosine kinase (SYK). In turn, SYK phosphorylates several
  downstream kinases, including Bruton’s tyrosine kinase (BTK) and phosphoinositide
  kinase-3 (PI3K). PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2)
  on the plasma membrane to generate the second messenger, phosphatidylinositol-3,4,5-trisphosphate
  (PIP3). PI3K phosphorylates phosphoinositide-dependent kinase 1 (PDK1) and the serine/threonine
  kinase AKT (Thr308), which activates the mammalian target of rapamycin (mTOR) and
  nuclear factor-κB (NF-κB) by inactivating the TSC1/2 inhibitor and by activating
  the inhibitor of nuclear factor-κB kinase (IKK), respectively. B-cell activating
  factor belonging to the TNF family (BAFF) receptor signaling cross-talks with BCR
  and activates NF-κB. NF-κB transcription factors form heterodimers and homodimers
  to activate the transcription of genes involved in cell survival, proliferation,
  and apoptosis. Several steps in these signaling pathways are altered in MCL. Blue
  symbols indicate inactivated or downregulated molecules in MCL; green symbols indicate
  activated or overexpressed molecules in MCL. Arrows indicate activating connections,
  and lines indicate inhibitory effects
papertitle: Potential effects of CRM1 inhibition in mantle cell lymphoma.
reftext: Ke-Jie Zhang, et al. Chin J Cancer Res. 2012 Dec;24(4):374-387.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9624664
figid_alias: PMC3551337__F2
figtype: Figure
redirect_from: /figures/PMC3551337__F2
ndex: cd71fb5e-ded9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3551337__cjcr-24-04-374-f2.html
  '@type': Dataset
  description: Major pathogenic lesions in MCL. The B-cell receptor (BCR) signaling
    pathway is initiated through the phosphorylation of coreceptors Igα (CD79α) and
    Igβ (CD79β), which recruits spleen tyrosine kinase (SYK). In turn, SYK phosphorylates
    several downstream kinases, including Bruton’s tyrosine kinase (BTK) and phosphoinositide
    kinase-3 (PI3K). PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2)
    on the plasma membrane to generate the second messenger, phosphatidylinositol-3,4,5-trisphosphate
    (PIP3). PI3K phosphorylates phosphoinositide-dependent kinase 1 (PDK1) and the
    serine/threonine kinase AKT (Thr308), which activates the mammalian target of
    rapamycin (mTOR) and nuclear factor-κB (NF-κB) by inactivating the TSC1/2 inhibitor
    and by activating the inhibitor of nuclear factor-κB kinase (IKK), respectively.
    B-cell activating factor belonging to the TNF family (BAFF) receptor signaling
    cross-talks with BCR and activates NF-κB. NF-κB transcription factors form heterodimers
    and homodimers to activate the transcription of genes involved in cell survival,
    proliferation, and apoptosis. Several steps in these signaling pathways are altered
    in MCL. Blue symbols indicate inactivated or downregulated molecules in MCL; green
    symbols indicate activated or overexpressed molecules in MCL. Arrows indicate
    activating connections, and lines indicate inhibitory effects
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNFSF13B
  - PHF11
  - PIK3AP1
  - BCR
  - RN7SL263P
  - CUX1
  - SART3
  - PTEN
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - SYK
  - PLCG1
  - PLCG2
  - TRAF3
  - TRAF2
  - TANK
  - BIRC2
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - PDK1
  - PDPK1
  - MAP3K14
  - MAP4K4
  - PRKCB
  - FXYD5
  - AKT1
  - AKT2
  - AKT3
  - EIF4EBP1
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - IKBKG
  - CHUK
  - TSC2
  - RPS6KB1
  - NFKB2
  - OAS3
  - PMEL
  - TPX2
  - SND1
  - ASCC2
  - RPTOR
  - LRPAP1
  - RELB
  - FKBP4
  - GTF2H4
  - PMPCB
  - PSIP1
  - H3P42
  - TNFAIP3
  - IGKV1-27
  - NFKB1
  - RELA
  - REL
  - SYT1
  - GORASP1
  - WNK1
  - CCND1
  - CDKN2A
  - H3P10
  - CDKN2B
  - MRPL28
  - SUB1
  - NXT1
  - H3P9
  - CCNE1
  - CCNE2
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDK2
  - MDM2
  - ATM
  - TP53
  - TP63
  - TP73
  - CD40
  - ASCC1
  - H3P40
  - ag
  - RhoGAP1A
  - mol
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - Pten
  - Myb
  - Pi3K21B
  - Taf5
  - Shark
  - sl
  - Traf-like
  - Traf6
  - Sin1
  - Pdk1
  - Mtor
  - Tor
  - Lst8
  - Ni-K
  - msn
  - ca
  - Ric
  - Akt
  - Thor
  - foxo
  - key
  - gig
  - S6k
  - Tudor-SN
  - Pep
  - Crtc
  - Rap1
  - fzr
  - mrn
  - Dif
  - dl
  - Rel
  - wash
  - norpA
  - Pka-C1
  - Zdhhc8
  - Arpc5
  - Su(osk)P16
  - dap
  - Nxt1
  - CycE
  - DCTN6-p27
  - CG9588
  - Cdk2
  - LanB2
  - anon-70Db
  - cyc
  - tefu
  - p53
  - betaTub60D
  - hth
  - Hrb27C
  - Rpt5
  - DCTN2-p50
  - Cancer
---
